Citations

Mayo Clinic

Showing 10 of 108551 citations.

Successful treatment of ulcerated hemangioma with diversion colostomy in a neonate with LUMBAR syndrome
Shah, A. , Tollefson, Megha M. , Ahn, Edward S. , Polites, Stephanie F. , Shah, Ananya , Polites, Stephanie, Gibreel, Waleed

Journal of Surgical Case Reports | March 8, 2024 | Volume: 2024 | Issue: 3 | Pages: No page available

10.1093/jscr/rjae114 | PMID 38463743 Get It

Abstract We present the case of a 3-week-old girl with LUMBAR syndrome, a rare condition involving segmental infantile hemangiomas (IH) in the lumbosacral region, myelopathy, and other congenital anomalies. The patient developed severe ulceration of a left buttock IH. Treatment included broad-spectrum antibiotics, debridement, and a laparoscopic temporary colostomy. Propranolol therapy, wound care, and fecal diversion led to successful healing of the ulceration. The report highlights the challenges of ulcerated IH in the perineal area due to exposure to urine and stool. The comprehensive approach resulted in positive outcomes, including the successful surgical treatment of spinal dysraphism, successful colostomy reversal, and developmental progress. This case contributes insight into the surgical management of severe perianal ulcerated IH associated with LUMBAR syndrome, highlighting the importance of a tailored surgical approach with a multidisciplinary framework.
Spontaneous Coronary Artery Dissection with Cardiogenic Shock in the United States
Krittanawong, Chayakrit , Patel, Neelkumar , Qadeer, Yusuf Kamran , Maitra, Neil Sagar , Sharma, Samin K. , Jneid, Hani , Bandyopadhyay, Dhrubajyoti , Wang, Zhen , Alam, Mahboob

Reviews in Cardiovascular Medicine | March 8, 2024 | Volume: 25 | Issue: 3 | Pages: No page available

10.31083/j.rcm2503086 | PMID 39076947 Get It

Background: Spontaneous coronary artery dissection (SCAD) is defined as a non-traumatic separation of the epicardial coronary artery walls that creates a false lumen. SCAD poses a difficult challenge in management, as decisions regarding revascularization and medical management seem to be tailored to the individual patient. We evaluated and compared outcomes based on cardiogenic shock in patients with SCAD utilizing Nationwide Readmissions Database (NRD) between January 1, 2016, to December 30, 2020. Methods: We utilized the NRD 2016–2019 to carry out this study. We evaluated demographics (e.g., age, gender), conventional risk factors, comorbidities present on the index admission, and in-hospital outcomes using their specific ICD-10-CM codes. The primary outcomes were In-hospital mortality and 30-day readmission, and the secondary outcome was to compare the complications in SCAD patient with cardiogenic shock (CS) compared to those without CS. Results: We analyzed 2473 individuals with SCAD, 2199 of these individuals did not have cardiogenic shock whereas 274 of these individuals did have cardiogenic shock. When comparing SCAD with cardiogenic shock to SCAD without cardiogenic shock, there was a statistically significant increased odds ratio (OR) for death (propensity matched OR 24.93 (7.49–83.05), use of mechanical circulatory support (propensity matched OR 15.30 (6.87–34.04), ventricular tachycardia (propensity matched OR 4.45 (1.92–10.34), utilization of blood transfusions (propensity matched OR 3.82 (1.86–7.87), acute kidney injury (propensity matched OR 4.02 (1.45–11.13), need for mechanical ventilation (propensity matched OR 8.87 (3.53–22.31), and respiratory failure (propensity matched OR 4.95 (1.83–13.41)))))))). There was no statistically significant difference in 30-day readmission rates between the two groups. Conclusions: SCAD is a unique condition that can lead to many complications. In our analysis, we showed that SCAD associated with cardiogenic shock compared to SCAD not associated with cardiogenic shock results in greater odds of complications including death, use of mechanical circulatory support, need for blood transfusions, ventricular tachycardia, acute kidney injury, use of mechanical ventilation, and respiratory failure. SCAD with cardiogenic shock represents a significantly critical clinical scenario that requires a multi-disciplinary approach to prevent the many potential complications associated with this disease process.
Cerebral microbleeds: Causes, clinical relevance, and imaging approach – A narrative review
Sharma, Preetika, Kanekar, Sangam , Ajmera, Pranav , Agarwal, Amit , Ajmera, Pranav

Journal of Neurosciences in Rural Practice | March 8, 2024 | Volume: 15 | Issue: No issue available | Pages: 169-181

10.25259/jnrp_351_2023 | PMID 38746527 Get It

With advances in magnetic resonance imaging (MRI) sequences, there has been increased identification of microbleed/microhemorrhage across different population ages, but more commonly in the older age group. These are defined as focal areas of signal loss on gradient echo MRI sequences (T2* and susceptibility-weighted images), which are usually <5 mm in size representing hemosiderin deposition with wide ranges of etiologies. Susceptibility-weighted imaging (SWI) has become a routine MRI sequence for practices across the globe resulting in better identification of these entities. Over the past decade, there has been a better understanding of the clinical significance of microbleeds including their prognostic value in ischemic and hemorrhagic stroke. Cerebral amyloid angiopathy and hypertension are the two most common causes of microbleeds following peripheral and central pattern, respectively. In the younger age group, microbleeds are more common due to familial conditions or a wide range of hypercoagulable states. This review outlines the pathophysiology, prevalence, and clinical implications of cerebral microhemorrhage along with a brief discussion about the technical considerations of SWI.
Integrating Retrieval-Augmented Generation with Large Language Models in Nephrology: Advancing Practical Applications
Miao, Jing , Suppadungsuk, Supawadee , Valencia, Oscar A. Garcia , Cheungpasitporn, Wisit , Suppadungsuk, Supawadee , Garcia-Valencia, Oscar , Cheungpasitporn, Wisit , Miao, Jing , Thongprayoon, Charat

Medicina | March 8, 2024 | Volume: 60 | Issue: 3 | Pages: 445

10.3390/medicina60030445 | PMID 38541171 Get It

The integration of large language models (LLMs) into healthcare, particularly in nephrology, represents a significant advancement in applying advanced technology to patient care, medical research, and education. These advanced models have progressed from simple text processors to tools capable of deep language understanding, offering innovative ways to handle health-related data, thus improving medical practice efficiency and effectiveness. A significant challenge in medical applications of LLMs is their imperfect accuracy and/or tendency to produce hallucinations—outputs that are factually incorrect or irrelevant. This issue is particularly critical in healthcare, where precision is essential, as inaccuracies can undermine the reliability of these models in crucial decision-making processes. To overcome these challenges, various strategies have been developed. One such strategy is prompt engineering, like the chain-of-thought approach, which directs LLMs towards more accurate responses by breaking down the problem into intermediate steps or reasoning sequences. Another one is the retrieval-augmented generation (RAG) strategy, which helps address hallucinations by integrating external data, enhancing output accuracy and relevance. Hence, RAG is favored for tasks requiring up-to-date, comprehensive information, such as in clinical decision making or educational applications. In this article, we showcase the creation of a specialized ChatGPT model integrated with a RAG system, tailored to align with the KDIGO 2023 guidelines for chronic kidney disease. This example demonstrates its potential in providing specialized, accurate medical advice, marking a step towards more reliable and efficient nephrology practices.
Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease
Orr, Miranda E. , Garbarino, Valentina R. , Palavicini, Juan Pablo , Melendez, Justin , Barthélemy, Nicolas R. , He, Yingxin , Kautz, Tiffany F. , Mathews, Julia, Zhang, Bin , Saliba, Afaf, Ragi, Nagarjunachary, Craft, Suzanne , Petersen, Ronald C. , Espíndola‐Netto, Jair Machado , Xue, Ailing, Kirkland, James L. , Salardini, Arash , Musi, Nicolas , Gonzales, Mitzi M. , Palavicini, Juan Pablo , Melendez, Justin , Barthélemy, Nicolas R , He, Yingxin , Xu, Peng , Saliba, Afaf , Petersen, Ronald C , Espindola-Netto, Jair Machado, Tchkonia, Tamara, Kirkland, James L , Seshadri, Sudha , Bateman, Randall J , Orr, Miranda E , Gonzales, Mitzi , Garbarino, Valentina, Kautz, Tiffany, Lopez-Cruzan, Marisa, Mathews, Julia, Zhang, Bin, Ragi, Nagarjunachary, Sharma, Kumar, Craft, Suzanne, Espindola-Netto, Jair, Xue, Ailing, Tchkonia, Tamara, Salardini, Arash, Musi, Nicolas, Gonzales, Mitzi

No container title available | March 8, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3994894/v1 | PMID 38496619 Get It

Abstract Senescent cell accumulation contributes to the progression of age-related disorders including Alzheimer’s disease (AD). Clinical trials evaluating senolytics, drugs that clear senescent cells, are underway, but lack standardized outcome measures. Our team recently published data from the first open-label trial to evaluate senolytics (dasatinib plus quercetin) in AD. After 12-weeks of intermittent treatment, we reported brain exposure to dasatinib, favorable safety and tolerability, and modest post-treatment changes in cerebrospinal fluid (CSF) inflammatory and AD biomarkers using commercially available assays. Herein, we present more comprehensive exploratory analyses of senolytic associated changes in AD relevant proteins, metabolites, lipids, and transcripts measured across blood, CSF, and urine. These analyses included mass spectrometry for precise quantification of amyloid beta (Aß) and tau in CSF; immunoassays to assess senescence associated secretory factors in plasma, CSF, and urine; mass spectrometry analysis of urinary metabolites and lipids in blood and CSF; and transcriptomic analyses relevant to chronic stress measured in peripheral blood cells. Levels of Aß and tau species remained stable. Targeted cytokine and chemokine analyses revealed treatment-associated increases in inflammatory plasma fractalkine and MMP-7 and CSF IL-6. Urinary metabolites remained unchanged. Modest treatment-associated lipid profile changes suggestive of decreased inflammation were observed both peripherally and centrally. Blood transcriptomic analysis indicated downregulation of inflammatory genes including FOS, FOSB, IL1β, IL8, JUN, JUNB, PTGS2. These data provide a foundation for developing standardized outcome measures across senolytic studies and indicate distinct biofluid-specific signatures that will require validation in future studies. ClinicalTrials.gov: NCT04063124.
Neuromodulation: What the neurointerventionalist needs to know
Mensah‐Brown, Kobina , Naylor, Ryan M. , Graepel, Stephen , Brinjikji, Waleed , Mensah-Brown, Kobina G

Interventional Neuroradiology | March 8, 2024 | Volume: 32 | Issue: 4 | Pages: 1285-1295

10.1177/15910199231224554 | PMID 38454831 Get It

Neuromodulation is the alteration of neural activity in the central, peripheral, or autonomic nervous systems. Consequently, this term lends itself to a variety of organ systems including but not limited to the cardiac, nervous, and even gastrointestinal systems. In this review, we provide a primer on neuromodulation, examining the various technological systems employed and neurological disorders targeted with this technology. Ultimately, we undergo a historical analysis of the field's development, pivotal discoveries and inventions gearing this review to neuro-adjacent subspecialties with a specific focus on neurointerventionalists.
Making Meaning of Difficult Experiences: A Self-Guided Program
Paulson, Deirdre

Family Medicine | March 8, 2024 | Volume: 56 | Issue: 5 | Pages: 336-337

10.22454/fammed.2024.389696 Get It

Structural bases for stoichiometry‐selective calcium potentiation of a neuronal nicotinic receptor
Mazzaferro, Simone , Kang, Guipeun , Natarajan, Kathiresan , Hibbs, Ryan , Sine, Steven M. , Hibbs, Ryan E

British Journal of Pharmacology | March 8, 2024 | Volume: 181 | Issue: 13 | Pages: 1973-1992

10.1111/bph.16321 | PMID 38454578 Get It

Background and Purpose α4β2 nicotinic acetylcholine (nACh) receptors assemble in two stoichiometric forms, one of which is potentiated by calcium. The sites of calcium binding that underpin potentiation are not known. Experimental Approach To identify calcium binding sites, we applied cryo‐electron microscopy (cryo‐EM) and molecular dynamics (MD) simulations to each stoichiometric form of the α4β2 nACh receptor in the presence of calcium ions. To test whether the identified calcium sites are linked to potentiation, we generated mutants of anionic residues at the sites, expressed wild type and mutant receptors in clonal mammalian fibroblasts, and recorded ACh‐elicited single‐channel currents with or without calcium. Key Results Both cryo‐EM and MD simulations show calcium bound to a site between the extracellular and transmembrane domains of each α4 subunit (ECD‐TMD site). Substituting alanine for anionic residues at the ECD‐TMD site abolishes stoichiometry‐selective calcium potentiation, as monitored by single‐channel patch clamp electrophysiology. Additionally, MD simulation reveals calcium association at subunit interfaces within the extracellular domain. Substituting alanine for anionic residues at the ECD sites reduces or abolishes stoichiometry‐selective calcium potentiation. Conclusions and Implications Stoichiometry‐selective calcium potentiation of the α4β2 nACh receptor is achieved by calcium association with topographically distinct sites framed by anionic residues within the α4 subunit and between the α4 and β2 subunits. Stoichiometry‐selective calcium potentiation could result from the greater number of calcium sites in the stoichiometric form with three rather than two α4 subunits. The results are relevant to modulation of signalling via α4β2 nACh receptors in physiological and pathophysiological conditions.
Histologic analysis of pancreatic cystic lesions: Is tissue the issue?
AbiMansour, Jad P. , Law, Ryan , AbiMansour, Jad

Endoscopy International Open | March 7, 2024 | Volume: 12 | Issue: 03 | Pages: E341-E343

10.1055/a-2241-8038 | PMID 38464980 Get It

UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.
Yuan, Yuan , Wang, Cong , Bai, Chenguang , Zhang, Zhe , Zhou, Hao , Gao, Huanyao , Wang, Siwei

No container title available | March 7, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3878357/v1 Get It

Abstract Background: HER2-positive (HER2+) breast cancer accounts for 20–30% of all breast cancers. Although trastuzumab has significantly improved the survival of patients with HER2+ breast cancer, more than 70% of patients develop drug resistance within one year of treatment. Understanding the molecular mechanisms of trastuzumab resistance and identifying biomarkers that predict early trastuzumab resistance would greatly benefit patients receiving trastuzumab therapy. Methods: Differential-gene-expression analysis of trastuzumab-sensitive and resistant HER2+ breast cancer cell lines from GSE15043 was performed to identify the biomarkers associated with trastuzumab resistance. Differential biomarker expression was confirmed in FFPE tissues collected from clinical HER2+ breast cancer tumor samples that were sensitive or resistant to trastuzumab treatment. The function of the biomarkers associated with trastuzumab resistance was studied using western blotting, immunofluorescence, electron microscopy, and siRNA knockdown and overexpression to elucidate the role and mechanisms of the biomarker in affecting the trastuzumab response. Results: UGT1A7, a member of the uronic acid transferase family, was associated with trastuzumab resistance. UGT1A7 expression was downregulated in trastuzumab-resistant tumor tissues and in a cell line that developed trastuzumab resistance (BT474TR). Overexpressing UGT1A7 in BT474TR restored their sensitivity to trastuzumab treatment, whereas downregulating UGT1A7 expression in parental cells led to trastuzumab resistance. Importantly, UGT1A7 localized to the endoplasmic reticulum and altered stress responses. Furthermore, downregulating UGT1A7 expression promoted epithelial-to-mesenchymal transition (EMT) by affecting TWIST, SNAIL, and GRP78 expression and the AMP-activated protein kinase signaling pathway, thus contributing to trastuzumab resistance. Conclusions: This study demonstrated the important role and novel mechanisms of UGT1A7 in tumor responses to trastuzumab. Low UGT1A7 expression plays an important role in EMT and contributes to trastuzumab resistance. UGT1A7 has the potential to be developed as a biomarker for identifying patients who are resistant to trastuzumab treatment.